These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32812835)

  • 21. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies.
    Thomann M; Reckermann K; Reusch D; Prasser J; Tejada ML
    Mol Immunol; 2016 May; 73():69-75. PubMed ID: 27058641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.
    Liu L
    J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation of FX
    Liu W; Padmashali R; Monzon OQ; Lundberg D; Jin S; Dwyer B; Lee YJ; Korde A; Park S; Pan C; Zhang B
    Biotechnol Prog; 2021 Jan; 37(1):e3061. PubMed ID: 32748555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
    Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
    Front Immunol; 2019; 10():562. PubMed ID: 30984171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis.
    Ashraf SQ; Umana P; Mössner E; Ntouroupi T; Brünker P; Schmidt C; Wilding JL; Mortensen NJ; Bodmer WF
    Br J Cancer; 2009 Nov; 101(10):1758-68. PubMed ID: 19904275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel bicistronic gene design couples stable cell line selection with a fucose switch in a designer CHO host to produce native and afucosylated glycoform antibodies.
    Roy G; Martin T; Barnes A; Wang J; Jimenez RB; Rice M; Li L; Feng H; Zhang S; Chaerkady R; Wu H; Marelli M; Hatton D; Zhu J; Bowen MA
    MAbs; 2018 Apr; 10(3):416-430. PubMed ID: 29400603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Fc Gamma Receptor Glycoforms That Produce Differential Binding Kinetics for Rituximab.
    Hayes JM; Frostell A; Karlsson R; Müller S; Martín SM; Pauers M; Reuss F; Cosgrave EF; Anneren C; Davey GP; Rudd PM
    Mol Cell Proteomics; 2017 Oct; 16(10):1770-1788. PubMed ID: 28576848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.
    Kurogochi M; Mori M; Osumi K; Tojino M; Sugawara S; Takashima S; Hirose Y; Tsukimura W; Mizuno M; Amano J; Matsuda A; Tomita M; Takayanagi A; Shoda S; Shirai T
    PLoS One; 2015; 10(7):e0132848. PubMed ID: 26200113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
    Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
    J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of
    Van Coillie J; Schulz MA; Bentlage AEH; de Haan N; Ye Z; Geerdes DM; van Esch WJE; Hafkenscheid L; Miller RL; Narimatsu Y; Vakhrushev SY; Yang Z; Vidarsson G; Clausen H
    Front Immunol; 2022; 13():987151. PubMed ID: 36189205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
    Wada R; Matsui M; Kawasaki N
    MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
    Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
    Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fc gamma receptor glycosylation modulates the binding of IgG glycoforms: a requirement for stable antibody interactions.
    Hayes JM; Frostell A; Cosgrave EF; Struwe WB; Potter O; Davey GP; Karlsson R; Anneren C; Rudd PM
    J Proteome Res; 2014 Dec; 13(12):5471-85. PubMed ID: 25345863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of fucosylation inhibitors for production of afucosylated antibody.
    Xu P; Ou YC; Smith M; Paulson J; Schmidt MA; Kandari L; Parsons R; Khetan A
    Biotechnol Prog; 2024; 40(3):e3438. PubMed ID: 38415431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
    Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
    MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.
    Ahmed AA; Keremane SR; Vielmetter J; Bjorkman PJ
    J Struct Biol; 2016 Apr; 194(1):78-89. PubMed ID: 26850169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fc glycan sialylation of biotherapeutic monoclonal antibodies has limited impact on antibody-dependent cellular cytotoxicity.
    Branstetter E; Duff RJ; Kuhns S; Padaki R
    FEBS Open Bio; 2021 Nov; 11(11):2943-2949. PubMed ID: 34355537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - impact of effector cells.
    Chung S; Lin YL; Reed C; Ng C; Cheng ZJ; Malavasi F; Yang J; Quarmby V; Song A
    J Immunol Methods; 2014 May; 407():63-75. PubMed ID: 24704820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of site-distinct N-glycan variants for in vitro bioactivity testing.
    Brühlmann D; Vuillemin T; Satwekar A; Galano E; Palmese A; D'Angelo A; Manco Z; Souquet J; Broly H; Sauer M; Hemberger J; Jordan M
    Biotechnol Bioeng; 2019 May; 116(5):1017-1028. PubMed ID: 30659587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FcγRIIIa chromatography to enrich a-fucosylated glycoforms and assess the potency of glycoengineered therapeutic antibodies.
    Freimoser-Grundschober A; Rueger P; Fingas F; Sondermann P; Herter S; Schlothauer T; Umana P; Neumann C
    J Chromatogr A; 2020 Jan; 1610():460554. PubMed ID: 31597603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.